Amylin Pharmaceuticals, Eli Lilly, and Alkermes Announce Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors

Amylin Pharmaceuticals, Inc. AMLN, Eli Lilly and Company LLY and Alkermes, Inc. ALKS today announced new analyses from the DURATION-3 and -4 trials demonstrating patients treated with the investigational medication BYDUREON™ (exenatide extended-release for injectable suspension) experienced significant improvements in select cardiovascular risk factors, in comparison to patients who received commonly prescribed diabetes treatments. The analyses showed that patients receiving BYDUREON for the treatment of type 2 diabetes experienced improvements in composite endpoints related to body weight, abnormal blood pressure and abnormal lipid levels. These findings will be presented at the 47th European Association for the Study of Diabetes Annual Meeting in Lisbon, Portugal.